What is GDNF?
Glial cell-derived neurotrophic factor (GDNF) is neuroprotective and neurorestorative to motor neurons and a range of neuromodulatory neurons including dopaminergic, noradrenergic, serotoninergic and acetylcholinergic neurons. GDNF’s potent neuroprotective and neurorestorative effects have been shown in pre-clinical models of PD, Multi System Atrophy, ALS, SCI, and epilepsy.
About US
Innervate Therapeutics Ltd is positioned to maximise the neurorestorative potential of GDNF using patent protected, novel and scalable delivery methods and technology for which it has licenced exclusive use for GDNF gene therapy applications.
Our Team
The company's products and technology exploit the globally recognised and pioneering clinical expertise of Professor Steven Gill in the direct, targeted delivery of therapeutic agents to the CNS. The company has significant clinical development experience in GDNF therapy and now plans to build an equally experienced commercial management team around a newly recruited CEO.
Our Progress
Proof of concept studies in large animal models have been successfully completed for its ALS indication. A formal pre-clinical large animal tox study is currently underway with a phase I/II study planned for 2023. Development of a gene therapy for Parkinson’s disease is also underway with the objective of completing a phase I/II clinical study in 2024.
